GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31

GT Biopharma, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$6.69−0.34 (-4.84%)

Close on Oct 19, 2026

Market cap: $259.71M
P/E (TTM): –
Dividend yield: –

GT Biopharma, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31	TTM Q3 2019 2019-09-30	TTM Q2 2019 2019-06-30	TTM Q1 2019 2019-03-31	TTM FY 2018 2018-12-31	TTM Q3 2018 2018-09-30	TTM Q2 2018 2018-06-30	TTM Q1 2018 2018-03-31	TTM FY 2017 2017-12-31	TTM Q3 2017 2017-09-30	TTM Q2 2017 2017-06-30	TTM Q1 2017 2017-03-31	TTM FY 2016 2016-12-31	TTM Q3 2016 2016-09-30
Stock-Based Compensation	–	0.48	0.43	0.39	0.02	0.13	0.23	–	–	–	–	–	–	–	–	–	–	–	34	11	8.95	8.77	0.27	-0.89	1.75	2.74	5.31	7.71	6.91	9.20	9.70	12	135	132	130	127	4.06	4.34	6.59	7.75
Change in Accounts Payable	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-1.47	-1.51	-1.40	-0.84	3.22	3.19	3.12	3.15	1.29	0.74	1.49	0.14	-0.52	-0.45	0.36	1.41	2.29	2.59	2.36	2.81	2.26
Operating Cash Flow	-14	-13	-13	-11	-10	-11	-13	-12	-12	-10	-8.85	-11	-12	-13	-15	-15	-16	-17	-16	-14	-12	-11	-7.26	-5.82	-5.25	-2.92	-3.66	-4.42	-6.73	-7.41	-11	-12	-10	-9.01	-5.43	-3.41	-1.74	-2.41	-1.93	-2.74
Capital Expenditures	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	-0.03	-0.03	-0.03	-0.04	-0.01	-0.01	-0.01	0.00	–	–	–	–	–
Purchase of Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Investing Cash Flow	–	–	–	–	–	–	13	13	15	10	-2.01	5.02	3.20	1.62	12	7.63	–	–	-23	–	–	–	0	–	–	–	0.20	0.17	-0.03	-0.03	-0.04	-0.01	-0.01	-0.01	0.00	–	–	–	–	–
Dividends Paid	–	–	-0.23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Stock Issued	–	–	–	–	–	–	–	–	–	–	6.27	–	–	–	–	–	–	–	25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Financing Cash Flow	14	20	16	7.47	6.49	–	2.98	–	–	–	6.27	6.27	6.27	–	-0.22	–	–	–	42	49	50	38	13	5.86	5.63	2.68	3.43	3.33	5.93	4.63	10	10	11	12	5.99	5.99	1.42	2.62	1.90	2.85
Net Change in Cash	-0.27	6.56	2.86	-3.89	-3.93	0.51	2.97	3.86	6.48	-0.10	-4.59	0.18	-2.59	-5.24	-3.30	-7.22	-34	-20	3.67	9.33	39	28	5.27	0.04	0.59	-0.05	-0.03	-0.92	-0.83	-2.82	-0.52	-1.50	1.06	2.64	0.56	2.58	-0.32	0.21	-0.03	0.11
Free Cash Flow	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-3.66	-4.45	-6.76	-7.45	-11	-12	-10	-9.01	-5.43	–	–	–	–	–
Income Taxes Paid	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0	0	0	0	0	0	–	–	–	–	–	–	–	–	0	0	0	0	0
Interest Paid	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.07	0	0	0	0.07	0	0	0	–	–	–	–	–	–	–	–	0	0	0	0	0

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -1377.4%

Financial strength

Current ratio: 2.61
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 223.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 72.77
Dividend yield: –